2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.31 Liu

PP01.31 Liu - Abstract

Pdf Summary

A study conducted at Memorial Sloan Kettering Cancer Center focused on patients with KRAS G12D mutant non-small cell lung cancer (NSCLC) identified through circulating tumor DNA (ctDNA) analysis. KRAS mutations were detected using next-generation sequencing of plasma ctDNA. Results from 230 patients showed KRAS G12C mutations were predominant, while 17.8% had KRAS G12D mutations, with a younger median age and faster turnaround time for ctDNA analysis compared to tissue sequencing. KRAS G12D was more common in never smokers and associated with shorter median overall survival compared to smokers, although the sample size was small. Patients tested before initial treatment received first-line anti-PD-(L)1 immunotherapy or chemoimmunotherapy with a median time to treatment discontinuation of 3.0 months. The study highlights the potential of plasma ctDNA analysis in identifying KRAS G12D mutant NSCLC, especially in never smokers, and suggests the urgent need for targeted therapies due to poor outcomes with standard treatments.

Keywords

KRAS G12D mutant non-small cell lung cancer

Memorial Sloan Kettering Cancer Center

circulating tumor DNA analysis

plasma ctDNA

next-generation sequencing

KRAS G12C mutations

KRAS G12D mutations

anti-PD-(L)1 immunotherapy

chemoimmunotherapy

plasma ctDNA analysis